Nanotheranostics for personalized medicine
- 1 April 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Molecular Diagnostics
- Vol. 13 (3), 257-269
- https://doi.org/10.1586/erm.13.15
Abstract
Nanotheranostics, the integration of diagnostic and therapeutic function in one system using the benefits of nanotechnology, is extremely attractive for personalized medicine. Because treating cancer is not a one-size-fits-all scenario, it requires therapy to be adapted to the patient’s specific biomolecules. Personalized and precision medicine (PM) does just that. It identifies biomarkers to gain an understanding of the diagnosis and in turn treating the specific disorder based on the precise diagnosis. By predominantly utilizing the unique properties of nanoparticles to achieve biomarker identification and drug delivery, nanotheranostics can be applied to noninvasively discover and target image biomarkers and further deliver treatment based on the biomarker distribution. This is a large and hopeful role theranostics must fill. However, as described in this expert opinion, current nanotechnology-based theranostics systems engineered for PM applications are not yet sufficient. PM is an ever-growing field that will be a driving force for future discoveries in biomedicine, especially cancer theranostics. In this article, the authors dissect the requirements for successful nanotheranostics-based PM.Keywords
This publication has 82 references indexed in Scilit:
- Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancerBiomaterials, 2012
- PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2European Journal of Nuclear Medicine and Molecular Imaging, 2012
- Multiplex Imaging of an Intracellular Proteolytic Cascade by using a Broad‐Spectrum NanoquencherAngewandte Chemie, 2012
- Cancer Theranostics with Near-Infrared Light-Activatable Multimodal NanoparticlesAccounts of Chemical Research, 2011
- First Experience with Clinical-Grade [18F]FPP(RGD)2: An Automated Multi-step Radiosynthesis for Clinical PET StudiesMolecular Imaging & Biology, 2011
- MicroPET Imaging of Integrin αvβ3 Expressing Tumors Using 89Zr-RGD PeptidesMolecular Imaging & Biology, 2010
- Nanoparticle-based theranostic agentsAdvanced Drug Delivery Reviews, 2010
- Peptide-Based Probes for Targeted Molecular ImagingBiochemistry, 2010
- Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug DeliveryMolecular Pharmaceutics, 2009
- Ultrasmall c(RGDyK)-Coated Fe3O4 Nanoparticles and Their Specific Targeting to Integrin αvβ3-Rich Tumor CellsJournal of the American Chemical Society, 2008